Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 16,507 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Connective Tissue Diseases Clear all
Completed Not applicable Interventional Results available

Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients

NCT01027416
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer

NCT00004038
View directory record Official record
Conditions
Breast Cancer
Interventions
Ad5CMV-p53 gene, chemotherapy
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

NCT01095848
View directory record Official record
Conditions
Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
Biological
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Buffalo, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 27, 2026, 5:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

NCT04752826
View directory record Official record
Conditions
Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
Interventions
BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection, Paclitaxel 80 mg/m2 weekly
Drug
Lead sponsor
BioInvent International AB
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
Duarte, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Technology to Scale-Up an Occupational Sun Protection Policy Program

NCT03278340
View directory record Official record
Conditions
Skin Cancer
Interventions
Sun Safe Workplaces - Technology, Sun Safe Workplaces -In Person
Behavioral
Lead sponsor
Klein Buendel, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,644 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Oakland, California • Golden, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

NCT03822468
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Anastrozole, Letrozole, Goserelin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
14
States / cities
Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 27, 2026, 5:17 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

NCT04496960
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
tofacitinib, Placebo
Drug · Other
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 27, 2026, 5:17 PM EDT
Terminated Phase 2 Interventional Results available

Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)

NCT03791060
View directory record Official record
Conditions
Necrobiosis Lipoidica Diabeticorum
Interventions
Secukinumab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 110 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 27, 2026, 5:17 PM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

NCT06072482
View directory record Official record
Conditions
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
Avacopan, Placebo, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
62
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 5:17 PM EDT
Completed No phase listed Observational

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

NCT02240784
View directory record Official record
Conditions
Acute Hepatic Porphyria
Interventions
Not listed
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores

NCT02779426
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Text messages
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
Up to 6 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 27, 2026, 5:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)

NCT00822276
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis, Eczema Herpeticum, MRSA
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
San Diego, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 27, 2026, 5:17 PM EDT
Active, not recruiting Phase 2 Interventional

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

NCT06100874
View directory record Official record
Conditions
Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
Interventions
Sacituzumab Govitecan, Trastuzumab, Trastuzumab and Hyaluronidase-oysk
Drug
Lead sponsor
Adrienne G. Waks
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • South Weymouth, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 27, 2026, 5:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

NCT07064018
View directory record Official record
Conditions
Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS Mutation-Related Tumors
Interventions
Spedox-6, Pegfilgrastim, Filgrastim
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

NCT02616614
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Onexton, Clindamycin/benzoyl peroxide gel, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
862 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Phoenix, Arizona • Chula Vista, California • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response

NCT02280252
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Radiation therapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Sorbent Therapy of the Cutaneous Porphyrias

NCT01422915
View directory record Official record
Conditions
Erythropoietic Protoporphyria
Interventions
Colestipol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
22 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 27, 2026, 5:17 PM EDT
Completed No phase listed Observational

Lung Disease Associated With Rheumatoid Arthritis

NCT00001876
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
21 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 27, 2026, 5:17 PM EDT
Terminated Phase 2 Interventional

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

NCT03342417
View directory record Official record
Conditions
Breast Cancer Female, Ovarian Cancer, Gastric Cancer
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
ExcellaBio LLC
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 2 Interventional

Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

NCT00107718
View directory record Official record
Conditions
Melanoma
Interventions
SB-485232
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 27, 2026, 5:17 PM EDT
Suspended No phase listed Observational

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)

NCT02313116
View directory record Official record
Conditions
Breast Cancer
Interventions
Interferometric Synthetic Aperture Microscopy
Device
Lead sponsor
Diagnostic Photonics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Cutera Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment

NCT03424304
View directory record Official record
Conditions
Wrinkle, Rosacea, Scarring
Interventions
Excel V™ Laser With Green Genesis
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 2 Interventional

A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers

NCT01070433
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
MEBO Wound Ointment (MEBO), Standard of Care
Drug · Other
Lead sponsor
Skingenix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Castro Valley, California • Encinitas, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

Great Auricular Nerve Block for Children Undergoing Tympanomastoid Surgery

NCT01638052
View directory record Official record
Conditions
Tympanomastoid Surgery, Cochlear Implant, Mastoidectomy, Cholesteatoma
Interventions
0.25% Bupivacaine + Clonidine
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 27, 2026, 5:17 PM EDT